Virax Biolabs Group annual shareholders’ equity
2021
2022
2023
2024
2025
2026
Virax Biolabs Group Shareholders’ Equity Growth & History (VRAX)
Virax Biolabs Group's shareholders’ equity was $7.6M for fiscal 2026.
View full Virax Biolabs Group company overviewVirax Biolabs Group annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $7.6M | $1.9M | +33.03% |
| 2025 | 2025-03-31 | $5.7M | $329,363 | +6.14% |
| 2024 | 2024-03-31 | $5.4M | −$3.8M | −41.20% |
| 2023 | 2023-03-31 | $9.1M | $10.1M | — |
| 2022 | 2022-03-31 | −$974,578 | −$323,896 | — |
| 2021 | 2021-03-31 | −$650,682 | — | — |
Virax Biolabs Group quarterly shareholders’ equity
Q4.21
Q4.22
Q4.23
Q4.24
Q4.25
Q2.26
Q4.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-03-31 | $7.6M | $1.9M | +33.03% |
| Q2 2026 | 2025-09-30 | $5.3M | — | — |
| Q4 2025 | 2025-03-31 | $5.7M | $329,363 | +6.14% |
| Q4 2024 | 2024-03-31 | $5.4M | −$3.8M | −41.20% |
| Q4 2023 | 2023-03-31 | $9.1M | $10.1M | — |
| Q4 2022 | 2022-03-31 | −$974,578 | −$323,896 | — |
| Q4 2021 | 2021-03-31 | −$650,682 | — | — |
Virax Biolabs Group shareholders’ equity trends
Over the last five fiscal years, Virax Biolabs Group's shareholders’ equity increased from −$650,682 to $7.6M, a change of $8.2M. The latest reported quarter, Q4 2026, shows $7.6M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Virax Biolabs Group source filings ↗